Excellence in life sciences executive search

Aeglea BioTherapeutics Builds Rare Disease Clinical Development Team Through Partnership With The Chase Group, Inc.

Through our ongoing partnership, Aeglea Biotherapeutics has secured a Vice President, Clinical Development, Rare Disease. The new Vice President will play a crucial role in advancing the clinical pipeline at Aeglea as they work to unlock the potential of engineered human enzymes to develop treatment options for patients with rare genetic diseases. The Chase Group is proud to connect this patient focused company with high caliber talent and wish Aeglea the best of success.

Copyright © 1993-2024 The Chase Group. All Rights Reserved.